Growth in its North American and Asia-Pacific markets helped drive a 14% sales gain in 2010 for radiation oncology firm Nucletron.
For the year (end-December 31), the company had sales of 128.2 million euros ($179.5 million U.S.), up from 112.9 million euros ($158.1 million U.S.) in 2009. Nucletron had earnings before interest, taxes, depreciation, and amortization (EBITDA) of 25.4 million euros ($35.6 million U.S.), compared with 2009 EBITDA of 20.1 million euros ($28.1 million U.S.)
For 2011, the company said it expects double-digit growth in sales and profitability and to further improve its position in all core markets.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
